Literature DB >> 20536931

Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury.

Tera Hasbargen1, Mostafa M Ahmed, Gurwattan Miranpuri, Lin Li, Kristopher T Kahle, Daniel Resnick, Dandan Sun.   

Abstract

Neuropathic pain is a common problem following spinal cord injury (SCI). Effective analgesic therapy has been hampered by the lack of knowledge about the mechanisms underlying post-SCI neuropathic pain. Current evidence suggests GABAergic spinal nociceptive processing is a critical functional node in this complex phenotype, representing a potential target for therapeutic intervention. Normal GABA neurotransmission is dependent on precise regulation of the level of intracellular chloride, which is determined by the coordinated activities of two cation/chloride cotransporters (CCCs) in the SLC12 family: the inwardly directed Na(+)-K(+)-Cl(-) cotransporter isoform 1 (NKCC1) and outwardly directed K(+)-Cl(-) cotransporter isoform 2 (KCC2). Inhibition of NKCC1 with its potent antagonist bumetanide reduces pain behavior in rats following SCI. Moreover, the injured spinal cord tissues exhibit a significant transient upregulation of NKCC1 protein and a concurrent downregulation of KCC2 protein. Thus, imbalanced function of NKCC1 and KCC2 may contribute to the induction and maintenance of the chronic neuropathic pain following SCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536931     DOI: 10.1111/j.1749-6632.2010.05462.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  56 in total

1.  Is it safe to use a diuretic to treat seizures early in development ?

Authors:  Y Ben-Ari; R Tyzio
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

Review 2.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

3.  Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate Biomarkers of Electrophysiologic Dysfunction.

Authors:  Gina Sizemore; Brandon Lucke-Wold; Charles Rosen; James W Simpkins; Sanjay Bhatia; Dandan Sun
Journal:  OBM Neurobiol       Date:  2018-06-04

4.  Acute spinal cord injury (SCI) transforms how GABA affects nociceptive sensitization.

Authors:  Yung-Jen Huang; Kuan H Lee; Lauren Murphy; Sandra M Garraway; James W Grau
Journal:  Exp Neurol       Date:  2016-09-15       Impact factor: 5.330

Review 5.  Is birth a critical period in the pathogenesis of autism spectrum disorders?

Authors:  Yehezkel Ben-Ari
Journal:  Nat Rev Neurosci       Date:  2015-07-08       Impact factor: 34.870

6.  Traumatic alterations in GABA signaling disrupt hippocampal network activity in the developing brain.

Authors:  Volodymyr Dzhala; Guzel Valeeva; Joseph Glykys; Rustem Khazipov; Kevin Staley
Journal:  J Neurosci       Date:  2012-03-21       Impact factor: 6.167

Review 7.  Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches.

Authors:  Dominic Schomberg; Gurwattan Miranpuri; Tyler Duellman; Andrew Crowell; Raghu Vemuganti; Daniel Resnick
Journal:  Metab Brain Dis       Date:  2015-01-15       Impact factor: 3.584

8.  Ionic plasticity and pain: The loss of descending serotonergic fibers after spinal cord injury transforms how GABA affects pain.

Authors:  Yung-Jen Huang; James W Grau
Journal:  Exp Neurol       Date:  2018-05-02       Impact factor: 5.330

9.  Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.

Authors:  Volodymyr Dzhala; Kevin J Staley
Journal:  CNS Neurosci Ther       Date:  2014-12-12       Impact factor: 5.243

10.  The enigmatic function of chandelier cells.

Authors:  Alan R Woodruff; Stewart A Anderson; Rafael Yuste
Journal:  Front Neurosci       Date:  2010-12-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.